Drug Insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting

@article{Oo2005DrugIN,
  title={Drug Insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting},
  author={T. Oo and P. Hesketh},
  journal={Nature Clinical Practice Oncology},
  year={2005},
  volume={2},
  pages={196-201}
}
  • T. Oo, P. Hesketh
  • Published 2005
  • Medicine
  • Nature Clinical Practice Oncology
  • Nausea and vomiting remain among the most feared side effects of chemotherapy for cancer patients. Significant progress has been made in the last 15 years in developing more effective and better-tolerated measures to minimize chemotherapy-induced nausea and vomiting (CINV). During the 1990s, the selective 5-hydroxytryptamine receptor antagonists were first introduced for the treatment of CINV, and resulted in more effective and better tolerated treatment of CINV. Despite recent progress… CONTINUE READING
    36 Citations

    Tables and Topics from this paper.

    Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
    • 177
    NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience.
    • M. Valerio, V. Gebbia, +5 authors Daniele Galanti
    • Medicine
    • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
    • 2020

    References

    SHOWING 1-10 OF 19 REFERENCES
    Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists
    • P. Hesketh
    • Medicine
    • Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
    • 1994
    • 52
    Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: A randomized double-blind trial in 866 patients.
    • 15